Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

Homepage
Tags search
Kite Pharma

CTech 24/7

More stories in CTech

Kite Pharma

12 stories about Kite Pharma

Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court
28.05.18|Zohar Shahar LevyIsraeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights
Israeli ALS Treatment Developer Recruits Kite Pharma's CSO as Board Member
05.02.18|Dror ReichNasdaq-listed BrainStorm develops stem cell therapies for degenerative neurological diseases
CTech’s Daily Israeli Tech News Roundup
16.01.18|CTechIsrael’s government and tech Industry brace for U.S. tax reform. Activist fund Elliott pushes to overhaul board of Israel's biggest telecom provider
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18|Zohar Shahar LevyZelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
CTech’s Daily Israeli Tech News Roundup
26.12.17|CTechImmunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall. Qatar is buying a lot of weapons to as a leverage against boycott. A $1.43 billion expansion plan announced for Israel’s main airport
Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall
26.12.17|Zohar Shahar LevyIn August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments
Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company
10.12.17|Lilach BaumerCalifornia-based Cell Design Labs will be acquired in a deal valued at up to $567 million
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17|Dror ReichFounder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17|Lilach BaumerThe cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Kite Pharma Sale Triggers Scientist Quarrel
02.10.17|Zohar Shahar LevyZelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients
30.08.17|Dror ReichWith two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
Gilead To Buy Kite Pharma for $11.9 Billion
29.08.17|Dror ReichThe drug company is looking to diversify into cell therapy following declining hepatitis c drug sales

About CTech Terms of Use Privacy Policy

Back to Top